The Use of Schisandrin B to Combat Triple-Negative Breast Cancers by Inhibiting NLRP3-Induced Interleukin-1β Production
Triple-negative breast cancer (TNBC) is the most aggressive and fatal breast cancer subtype. Nowadays, chemotherapy remains the standard treatment of TNBC, and immunotherapy has emerged as an important alternative. However, the high rate of TNBC recurrence suggests that new treatment is desperately...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-01-01
|
| Series: | Biomolecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-273X/14/1/74 |
| _version_ | 1797344560039329792 |
|---|---|
| author | Chun-Ming Chang Ting-Ruei Liang Ho Yin Pekkle Lam |
| author_facet | Chun-Ming Chang Ting-Ruei Liang Ho Yin Pekkle Lam |
| author_sort | Chun-Ming Chang |
| collection | DOAJ |
| description | Triple-negative breast cancer (TNBC) is the most aggressive and fatal breast cancer subtype. Nowadays, chemotherapy remains the standard treatment of TNBC, and immunotherapy has emerged as an important alternative. However, the high rate of TNBC recurrence suggests that new treatment is desperately needed. Schisandrin B (Sch B) has recently revealed its anti-tumor effects in cancers such as cholangiocarcinoma, hepatoma, glioma, and multi-drug-resistant breast cancer. However, there is still a need to investigate using Sch B in TNBC treatment. Interleukin (IL)-1β, an inflammatory cytokine that can be expressed and produced by the cancer cell itself, has been suggested to promote BC proliferation and progression. In the current study, we present evidence that Sch B can significantly suppress the growth, migration, and invasion of TNBC cell lines and patient-derived TNBC cells. Through inhibition of inflammasome activation, Sch B inhibits interleukin (IL)-1β production of TNBC cells, hindering its progression. This was confirmed using an NLRP3 inhibitor, OLT1177, which revealed a similar beneficial effect in combating TNBC progression. Sch B treatment also inhibits IL-1β-induced EMT expression of TNBC cells, which may contribute to the anti-tumor response. |
| first_indexed | 2024-03-08T11:04:29Z |
| format | Article |
| id | doaj.art-837d51be02d74575aec9aca84e0be233 |
| institution | Directory Open Access Journal |
| issn | 2218-273X |
| language | English |
| last_indexed | 2024-03-08T11:04:29Z |
| publishDate | 2024-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomolecules |
| spelling | doaj.art-837d51be02d74575aec9aca84e0be2332024-01-26T15:19:23ZengMDPI AGBiomolecules2218-273X2024-01-011417410.3390/biom14010074The Use of Schisandrin B to Combat Triple-Negative Breast Cancers by Inhibiting NLRP3-Induced Interleukin-1β ProductionChun-Ming Chang0Ting-Ruei Liang1Ho Yin Pekkle Lam2Department of General Surgery, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien 970473, TaiwanPhD Program in Pharmacology and Toxicology, Tzu Chi University, Hualien 970374, TaiwanDepartment of Biochemistry, School of Medicine, Tzu Chi University, Hualien 970374, TaiwanTriple-negative breast cancer (TNBC) is the most aggressive and fatal breast cancer subtype. Nowadays, chemotherapy remains the standard treatment of TNBC, and immunotherapy has emerged as an important alternative. However, the high rate of TNBC recurrence suggests that new treatment is desperately needed. Schisandrin B (Sch B) has recently revealed its anti-tumor effects in cancers such as cholangiocarcinoma, hepatoma, glioma, and multi-drug-resistant breast cancer. However, there is still a need to investigate using Sch B in TNBC treatment. Interleukin (IL)-1β, an inflammatory cytokine that can be expressed and produced by the cancer cell itself, has been suggested to promote BC proliferation and progression. In the current study, we present evidence that Sch B can significantly suppress the growth, migration, and invasion of TNBC cell lines and patient-derived TNBC cells. Through inhibition of inflammasome activation, Sch B inhibits interleukin (IL)-1β production of TNBC cells, hindering its progression. This was confirmed using an NLRP3 inhibitor, OLT1177, which revealed a similar beneficial effect in combating TNBC progression. Sch B treatment also inhibits IL-1β-induced EMT expression of TNBC cells, which may contribute to the anti-tumor response.https://www.mdpi.com/2218-273X/14/1/74triple-negative breast cancerSchisandrin Brecurrenceinflammasome activation |
| spellingShingle | Chun-Ming Chang Ting-Ruei Liang Ho Yin Pekkle Lam The Use of Schisandrin B to Combat Triple-Negative Breast Cancers by Inhibiting NLRP3-Induced Interleukin-1β Production Biomolecules triple-negative breast cancer Schisandrin B recurrence inflammasome activation |
| title | The Use of Schisandrin B to Combat Triple-Negative Breast Cancers by Inhibiting NLRP3-Induced Interleukin-1β Production |
| title_full | The Use of Schisandrin B to Combat Triple-Negative Breast Cancers by Inhibiting NLRP3-Induced Interleukin-1β Production |
| title_fullStr | The Use of Schisandrin B to Combat Triple-Negative Breast Cancers by Inhibiting NLRP3-Induced Interleukin-1β Production |
| title_full_unstemmed | The Use of Schisandrin B to Combat Triple-Negative Breast Cancers by Inhibiting NLRP3-Induced Interleukin-1β Production |
| title_short | The Use of Schisandrin B to Combat Triple-Negative Breast Cancers by Inhibiting NLRP3-Induced Interleukin-1β Production |
| title_sort | use of schisandrin b to combat triple negative breast cancers by inhibiting nlrp3 induced interleukin 1β production |
| topic | triple-negative breast cancer Schisandrin B recurrence inflammasome activation |
| url | https://www.mdpi.com/2218-273X/14/1/74 |
| work_keys_str_mv | AT chunmingchang theuseofschisandrinbtocombattriplenegativebreastcancersbyinhibitingnlrp3inducedinterleukin1bproduction AT tingrueiliang theuseofschisandrinbtocombattriplenegativebreastcancersbyinhibitingnlrp3inducedinterleukin1bproduction AT hoyinpekklelam theuseofschisandrinbtocombattriplenegativebreastcancersbyinhibitingnlrp3inducedinterleukin1bproduction AT chunmingchang useofschisandrinbtocombattriplenegativebreastcancersbyinhibitingnlrp3inducedinterleukin1bproduction AT tingrueiliang useofschisandrinbtocombattriplenegativebreastcancersbyinhibitingnlrp3inducedinterleukin1bproduction AT hoyinpekklelam useofschisandrinbtocombattriplenegativebreastcancersbyinhibitingnlrp3inducedinterleukin1bproduction |